Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway

Blood

Volumn 122, Issue 23, 2013, Pages 3808-3817

  Betapudi, Venkaiah ^a   Lominadze, George ^b   Hsi, Linda ^a   Willard, Belinda ^a   Wu, Meifang ^a   McCrae, Keith R ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 IODO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLEBBISTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MYOSIN II; MYOSIN IIA; MYOSIN LIGHT CHAIN KINASE; PHOSPHOLIPID ANTIBODY; PHOSPHOPROTEIN; RHO ASSOCIATED PROTEIN KINASE 1; RHO ASSOCIATED PROTEIN KINASE 2; RHO KINASE; SMALL INTERFERING RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; MOLECULAR MOTOR; MYOSIN LIGHT CHAIN; ROCK1 PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN; SELE PROTEIN, HUMAN;

ARTICLE; AUTORADIOGRAPHY; CELL ACTIVATION; CELL SURFACE; CYTOSKELETON; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INTRACELLULAR SIGNALING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; MOTOR ACTIVITY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MODEL; BLOOD; COMPLICATION; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; RABBIT; SIGNAL TRANSDUCTION; THROMBOSIS; DRUG ANTAGONISM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CELL-DERIVED MICROPARTICLES; E-SELECTIN; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR MOTOR PROTEINS; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN KINASE; NONMUSCLE MYOSIN TYPE IIA; PHOSPHORYLATION; RABBITS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84891124933     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-490318     Document Type: Article

References (50)

1. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109(2): 422-430.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
3. Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol. 2009;27(4):668-677.
4. De Groot PG, Meijers JC, Urbanus RT. Recent developments in our understanding of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34(3):223-231.
5. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990; 87(11):4120-4124.
6. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-1547.
7. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7(11):1767-1773.
8. de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein I. Blood. 2012;120(2):266-274.
9. Del Papa N, Sheng YH, Raschi E, et al. Human β 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β 2-glycoprotein I antibodies. J Immunol. 1998;160(11):5572-5578.
10. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/antiβ2 glycoprotein I antibodies. Blood. 2012;119(3): 884-893.
11. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/antiβ2 glycoprotein I antibodies. Blood. 2005;105(5): 1964-1969.
12. de Groot PG, Derksen RH, Urbanus RT. The role of LRP8 (ApoER2′) in the pathophysiology of the antiphospholipid syndrome. Lupus. 2010;19(4): 389-393.
13. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyteendothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest. 2011;121(1):120-131.
14. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008;34(3): 236-250.
15. Urbanus RT, de Laat B. Antiphospholipid antibodies and the protein C pathway. Lupus. 2010;19(4):394-399.
16. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163(3):1193-1200.
17. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995; 96(5):2211-2219.
18. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40(3):551-561.
19. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101(9):3495-3500.
20. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost. 2007;5(9):1828-1834.
21. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88(2):245-250.
22. Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus. 1996;5(5):440-441.
23. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol. 1993;168(1 Pt 1):206-210.
24. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104(1):93-102.
25. Roos MA, Gennero L, Denysenko T, et al. Microparticles in physiological and in pathological conditions. Cell Biochem Funct. 2010;28(7):539-548.
26. Morel O, Morel N, Jesel L, Freyssinet JM, Toti F. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol. 2011;33(5):469-486.
27. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res. 2008;122(5): 604-609.
28. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91(4):667-673.
29. Owens AP III, Mackman NM. MP's and VTE's: fact or fiction. Thromb Res. 2011;128(6):505-506.
30. Distler JHW, Huber LC, Gay S, Distler O, Pisetsky DS. Microparticles as mediators of cellular crosstalk in inflammatory disease. Autoimmunity. 2006; 39(8):683-690.
31. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):15-26.
32. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000; 275(20):15541-15548.
33. Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood. 2011;117(23):6383-6391.
34. Butt E, Gambaryan S, Göttfert N, Galler A, Marcus K, Meyer HE. Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem. 2003;278(18):15601-15607.
35. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, McLeish KR. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics. 2005;4(10):1503-1521.
36. Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res. 2006;66(9):4725-4733.
37. Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and antiendothelial cell antibodies III: β 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995; 13(2):179-185.
38. Nguyen DH, Catling AD, Webb DJ, et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol. 1999; 146(1):149-164.
39. Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of the NF-κB/Rel proteins via the p38 mitogen activated protein kinase, and of the MEK1/ERK pathway. Arthritis Rheum. 2006;54(1):301-311.
40. Aronovich R, Gurwitz D, Kloog Y, Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology. 2005;210(10): 781-788.
41. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10(11): 778-790.
42. Goeckeler ZM, Bridgman PC, Wysolmerski RB. Nonmuscle myosin II is responsible for maintaining endothelial cell basal tone and stress fiber integrity. Am J Physiol Cell Physiol. 2008; 295(4):C994-C1006.
43. Sapet C, Simoncini S, Loriod B, et al. Thrombininduced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006;108(6): 1868-1876.
44. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol. 2011;31(8): 1898-1907.
45. Latham SL, Chaponnier C, Dugina V, Couraud PO, Grau GE, Combes V. Cooperation between β- and γ-cytoplasmic actins in the mechanical regulation of endothelial microparticle formation. FASEB J. 2013;27(2): 672-683.
46. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 2004; 9:1118-1135.
47. Pericleous C, Giles I, Rahman A. Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus. 2009;18(8):671-675.
48. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64(8): 2719-2723.
49. Pericleous C, Clarke LA, Brogan PA, et al. Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. Thromb Haemost. 2013;109(1):72-78.
50. Nguyen DHD, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998; 273(14):8502-8507.